tifacogin

Tifacogin is a recombinant form of tissue factor pathway inhibitor (TFPI), developed as an anticoagulant therapy. It acts by inhibiting the tissue factor (TF)-initiated coagulation cascade, specifically targeting and inhibiting the activity of coagulation factors VIIa and Xa, thereby reducing thrombin generation and fibrin formation. Tifacogin was primarily investigated for use in severe sepsis, septicemia, and community-acquired pneumonia to reduce mortality associated with coagulopathy in these conditions. Despite showing biological activity—such as lowering prothrombin fragment 1.2 and thrombin-antithrombin complex levels—clinical trials did not demonstrate a significant overall survival benefit in the primary efficacy populations[1][3][7]. The drug was developed by Chiron Corp., later acquired by Novartis[4][5].

Other names

recombinant tissue factor pathway inhibitorrTFPI